ALDH1A1 and breast carcinoma: In addition, preclinical studies have confirmed that DSF in combination with gemcitabine or programmed death‐ligand 1 (PD‐L1) antibody efficiently inhibits 4T1 breast cancer tumorigenicity and growth by targeting ALDH1A1 enriched CSCs and MDSCs, respectively.119